Shows
Adis Journal PodcastsHER2-Mutant Non-Small Cell Lung Cancer Podcast: Finding Patients (Episode 2)
In episode 2 in our podcast series, Vivek Subbiah from the Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA, and Martin Dietrich from the US Oncology Network and Cancer Care Centers of Brevard, Orlando, FL, USA focus on the critical challenge of identifying patients with HER2-mutant non-small cell lung cancer (NSCLC).
This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-026-01215-2. All conflicts of interest can be...
2026-05-1324 min
Adis Journal PodcastsHER2-mutant Non-small Cell Lung Cancer Podcast: Knowledge Is Power (Episode 1)
In the first episode of our podcast series, Vivek Subbiah from the Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA, Martin Dietrich from the US Oncology Network and Cancer Care Centers of Brevard, Orlando, FL, USA, and Xiuning Le from the University of Texas MD Anderson Cancer Center, Houston, TX, USA introduce the emerging landscape of HER2-mutant non-small cell lung cancer (NSCLC), highlighting its place within the broader context of lung cancer.
This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted...
2026-05-1318 min
ASCO EducationDesigning Clinical Trials for Patients With Rare Cancers: Connecting the ZebrasDr. Hope Rugo and Dr. Vivek Subbiah discuss innovative trial designs to enable robust studies for smaller patient populations, as well as the promise of precision medicine, novel therapeutic approaches, and global partnerships to advance rare cancer research and improve patient outcomes. TRANSCRIPT Dr. Hope Rugo: Hello and welcome to By the Book, a podcast series from ASCO that features engaging conversations between editors and authors of the ASCO Educational Book. I am your host, Dr. Hope Rugo. I am the director of the Women's Cancers Program and division chief of breast medical oncology at...
2026-01-1224 min
Perspectives by the Leerink Center for PharmacoeconomicsDavid Hong, MD, Steve Potts, PhD, MBA, and Vivek Subbiah, MD talk Pan-Tumor Approvals in a Post-IRA WorldMelanie Whittington, Head of the Leerink Center for Pharmacoeconomics, talks with Vivek Subbiah, MD, David Hong, MD, and Steve Potts, PhD, MBA to discuss if pan-tumor approval strategies offer a path forward for broader, faster adoption across larger patient populations. Given the slow adoption curves typical of new therapeutics and the potential for government price negotiation as early as nine years after market entry, the experts hash out if pan-tumor approval is a potential development and commercialization pathway to ramp up clinical adoption and sales early on. They discuss the challenges, data requirements, and opportunities of this relatively new development...
2025-12-0242 min
JAMA NetworkJAMA Oncology : Metastatic Recurrence Among Adolescents and Young Adults With CancerInterview with Ann Brunson, MS, and Theresa H. M. Keegan, PhD, MS, authors of Metastatic Recurrence Among Adolescents and Young Adults With Cancer. Hosted by Vivek Subbiah, MD. Related Content: Metastatic Recurrence Among Adolescents and Young Adults With Cancer Metastatic Recurrence in Adolescent and Young Adult Cancer—Key Drivers of Early Mortality
2025-11-2611 minJAMA Oncology Author InterviewsMetastatic Recurrence Among Adolescents and Young Adults With CancerInterview with Ann Brunson, MS, and Theresa H. M. Keegan, PhD, MS, authors of Metastatic Recurrence Among Adolescents and Young Adults With Cancer. Hosted by Vivek Subbiah, MD. Related Content: Metastatic Recurrence Among Adolescents and Young Adults With Cancer Metastatic Recurrence in Adolescent and Young Adult Cancer—Key Drivers of Early Mortality
2025-11-2611 min
Healthcare Unfiltered ExpressEpisode 31: Tumor-Agnostic TherapiesShould we treat cancers regardless of where they had originated from? Dr. Vivek Subbiah, world-renowned oncologist and researcher, joined Healthcare Unfiltered EXPRESS to advocate that this is the way of the future. A must listen episode looking into the future of cancer therapeutics. Please subscribe, share, and join the conversation.
2025-11-1721 min
JAMA Oncology Author InterviewsConsistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and MortalityInterview with Yiwen Zhang, PhD, and Edward L. Giovannucci, MD, ScD, authors of Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality. Hosted by Vivek Subbiah, MD. Related Content: Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality Long-Term Physical Activity for Prevention of Digestive System Cancers—Consistency Is Key
2025-10-3012 minJAMA NetworkJAMA Oncology : Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and MortalityInterview with Yiwen Zhang, PhD, and Edward L. Giovannucci, MD, ScD, authors of Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality. Hosted by Vivek Subbiah, MD. Related Content: Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality Long-Term Physical Activity for Prevention of Digestive System Cancers—Consistency Is Key
2025-10-3012 min
JAMA NetworkJAMA Oncology : Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic CancerInterview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD. Related Content: Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer
2025-09-1813 minJAMA Oncology Author InterviewsOral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic CancerInterview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD. Related Content: Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer
2025-09-1813 min
JAMA NetworkJAMA Oncology : Proportional Sedation for Persistent Agitated Delirium in Palliative CareInterview with David Hui, MD, and Eduardo Bruera, MD, authors of Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Proportional Sedation for Persistent Agitated Delirium in Palliative Care
2025-07-3117 minJAMA Oncology Author InterviewsProportional Sedation for Persistent Agitated Delirium in Palliative CareInterview with David Hui, MD, and Eduardo Bruera, MD, authors of Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Proportional Sedation for Persistent Agitated Delirium in Palliative Care
2025-07-3117 min
Healthcare UnfilteredEpisode 233: Vivek’s Takes: ASCO 2025Dr. Vivek Subbiah returns for another edition of Vivek’s Takes, offering his expert insights on the standout science from the 2025 ASCO Annual Meeting. He breaks down key developments including trispecific antibodies, the growing role of radioligand therapies, a new standard of care in small cell lung cancer, and paradigm-shifting data in adjuvant therapy for colorectal cancer. The discussion also highlights a long-term exercise intervention, adjuvant vaccine studies, ctDNA and MRD integration, resistance mechanisms, artificial intelligence, and other emerging trends shaping the future of oncology.Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chad...
2025-06-2438 min
JAMA NetworkJAMA Oncology : New Definition of Light Chain Monoclonal Gammopathy of Undetermined SignificanceInterview with Thorir Einarsson Long, MD, PhD, and Ola Landgren, MD, PhD, authors of New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance. Hosted by Vivek Subbiah, MD. Related Content: New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance
2025-05-2918 minJAMA Oncology Author InterviewsNew Definition of Light Chain Monoclonal Gammopathy of Undetermined SignificanceInterview with Thorir Einarsson Long, MD, PhD, and Ola Landgren, MD, PhD, authors of New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance. Hosted by Vivek Subbiah, MD. Related Content: New Definition of Light Chain Monoclonal Gammopathy of Undetermined Significance
2025-05-2918 min
JAMA NetworkJAMA Oncology : Intravenous Magnesium and Cisplatin-Associated Acute Kidney InjuryInterview with Shruti Gupta, MD, MPH, author of Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury. Hosted by Vivek Subbiah, MD. Related Content: Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury
2025-04-2412 minJAMA Oncology Author InterviewsIntravenous Magnesium and Cisplatin-Associated Acute Kidney InjuryInterview with Shruti Gupta, MD, MPH, author of Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury. Hosted by Vivek Subbiah, MD. Related Content: Intravenous Magnesium and Cisplatin-Associated Acute Kidney Injury
2025-04-2412 min
JAMA Oncology Author InterviewsAccelerated Aging in Survivors of Childhood CancerInterview with Jennifer M. Yeh, PhD, and Lisa R. Diller, MD, authors of Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions. Hosted by Vivek Subbiah, MD. Related Content: Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer
2025-03-2019 minJAMA NetworkJAMA Oncology : Accelerated Aging in Survivors of Childhood CancerInterview with Jennifer M. Yeh, PhD, and Lisa R. Diller, MD, authors of Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions. Hosted by Vivek Subbiah, MD. Related Content: Accelerated Aging in Survivors of Childhood Cancer—Early Onset and Excess Risk of Chronic Conditions On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer
2025-03-2019 min
JAMA NetworkJAMA Oncology : Academic-Community Partnership and Deaths in Promyelocytic LeukemiaInterview with Anand P. Jillella, MD, author of Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial. Hosted by Vivek Subbiah, MD. Related Content: Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality
2025-02-2718 minJAMA Oncology Author InterviewsAcademic-Community Partnership and Deaths in Promyelocytic LeukemiaInterview with Anand P. Jillella, MD, author of Academic-Community Partnership and Deaths in Promyelocytic Leukemia: The Nonrandomized ECOG-ACRIN EA9131 Trial. Hosted by Vivek Subbiah, MD. Related Content: Academic Community Partnership in Acute Promyelocytic Leukemia and Early Mortality
2025-02-2718 min
JAMA NetworkJAMA Oncology : Intracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 TherapyInterview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD. Related Content: Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy
2025-01-3011 minJAMA Oncology Author InterviewsIntracranial Outcomes in Melanoma Brain Metastases After Anti–PD-1 TherapyInterview with Michael A. Postow, MD, author of Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy. Hosted by Vivek Subbiah, MD. Related Content: Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy
2025-01-3011 min
JAMA Oncology Author InterviewsEstimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020Interview with Katrina A. B. Goddard, PhD, author of Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. Hosted by Vivek Subbiah, MD. Related Content: Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020
2024-12-0516 minJAMA NetworkJAMA Oncology : Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020Interview with Katrina A. B. Goddard, PhD, author of Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. Hosted by Vivek Subbiah, MD. Related Content: Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020
2024-12-0516 min
Healthcare UnfilteredEpisode 207: Vivek's Takes: ESMO 2024 and AACR DebateDr. Vivek Subbiah returns for another edition of Vivek's Takes, sharing his insights on key updates from ESMO Congress 2024, including breakthroughs in neuroendocrine tumors, gastric cancer, and non-small cell lung cancer. He also delves into the highlights of his AACR debate on integrating early cancer detection with AI, arguing for the transformative potential of humans with AI versus the readiness of AI today. Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
2024-11-2630 min
JAMA Oncology Author InterviewsOlverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or AsciminibInterview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
2024-11-2118 minJAMA NetworkJAMA Oncology : Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or AsciminibInterview with Hagop Kantarjian, MD, author of Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
2024-11-2118 min
OncLive® On AirOngoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MDIn this episode of the Oncology Unplugged series, Chandler Park, MD, a genitourinary medical oncologist at Norton Cancer Institute in Louisville, Kentucky, hosted a conversation with Vivek Subbiah, MD, a medical oncologist and chief of Early-Phase Drug Development at Sarah Cannon Research Institute in Nashville, Tennessee. Dr Subbiah, an internationally recognized expert, discussed advancements in precision oncology, emphasizing the effects of next-generation sequencing and tissue-agnostic therapies on personalized cancer treatment. Dr Subbiah highlighted the transformation in genome sequencing that has taken place since the Human Genome Project, noting the reduction in sequencing costs from $3.3 billion to potentially $1 per genome. He...
2024-10-3020 min
JAMA NetworkJAMA Oncology : Anti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid CarcinomaInterview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
2024-10-2420 minJAMA Oncology Author InterviewsAnti–PD-L1 Plus Targeted Therapy in Anaplastic Thyroid CarcinomaInterview with Maria E. Cabanillas, MD, author of Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. Hosted by Vivek Subbiah, MD. Related Content: Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma
2024-10-2420 min
JAMA Oncology Author InterviewsLynch Syndrome and Somatic Mismatch Repair Variants in Pancreas CancerInterview with Eileen M. O'Reilly, MD, author of Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Hosted by Vivek Subbiah, MD. Related Content: Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
2024-09-0517 minJAMA NetworkJAMA Oncology : Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas CancerInterview with Eileen M. O’Reilly, MD, author of Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer. Hosted by Vivek Subbiah, MD. Related Content: Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer
2024-09-0517 min
JAMA NetworkJAMA Oncology : Identification of Immune Checkpoint Inhibitor–Induced DiabetesInterview with Michelle Rengarajan, MD, PhD, author of Identification of Immune Checkpoint Inhibitor–Induced Diabetes. Hosted by Vivek Subbiah, MD. Related Content: Identification of Immune Checkpoint Inhibitor–Induced Diabetes
2024-08-2914 minJAMA Oncology Author InterviewsIdentification of Immune Checkpoint Inhibitor–Induced DiabetesInterview with Michelle Rengarajan, MD, PhD, author of Identification of Immune Checkpoint Inhibitor–Induced Diabetes. Hosted by Vivek Subbiah, MD. Related Content: Identification of Immune Checkpoint Inhibitor–Induced Diabetes
2024-08-2914 min
JAMA NetworkJAMA Oncology : Neoadjuvant Exercise Therapy in Prostate CancerInterview with Lee W. Jones, PhD, author of Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized Controlled Trial. Hosted by Vivek Subbiah, MD. Related Content: Neoadjuvant Exercise Therapy in Prostate Cancer
2024-07-1819 minJAMA Oncology Author InterviewsNeoadjuvant Exercise Therapy in Prostate CancerInterview with Lee W. Jones, PhD, author of Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized Controlled Trial. Hosted by Vivek Subbiah, MD. Related Content: Neoadjuvant Exercise Therapy in Prostate Cancer
2024-07-1819 min
Healthcare UnfilteredEpisode 186: VIVEK'S TAKES on ASCO 2024Vivek Subbiah, MD, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute, kicks off his new series on Healthcare Unfiltered, “VIVEK’S TAKES,” in which he will provide his expert feedback on the importance and lasting effects of research presented at the top medical conferences in the world.In response to the 2024 ASCO Annual Meeting, Dr. Subbiah shares the themes he sees being developed in multiple cancer subspecialties, including breast, lung, and pancreatic, as well as the research-driven benefits of receiving care on clinical trials and early palliative care via telemedicine.Check out Chadi’s website for all Healthca...
2024-07-0230 min
JAMA NetworkJAMA Oncology : Endometrial Thickness as Diagnostic Triage for Endometrial Cancer in Black IndividualsInterview with Kemi M. Doll, MD, MSCR, author of Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals. Hosted by Vivek Subbiah, MD. Related Content: Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals
2024-06-2715 minJAMA Oncology Author InterviewsEndometrial Thickness as Diagnostic Triage for Endometrial Cancer in Black IndividualsInterview with Kemi M. Doll, MD, MSCR, author of Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals. Hosted by Vivek Subbiah, MD. Related Content: Endometrial Thickness as Diagnostic Triage for Endometrial Cancer Among Black Individuals
2024-06-2715 min
JAMA Oncology Author InterviewsT-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell TherapyInterview with Roni Shouval, MD, PhD, author of T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy. Hosted by Vivek Subbiah, MD. Related Content: T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy
2024-04-1819 min
JAMA Oncology Author InterviewsAnalysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel TimeInterview with Tobias Janowitz, MD, PhD, and Karen Winkfield, MD, PhD, authors of Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time. Hosted by Vivek Subbiah, MD. Related Content: Analysis and Optimization of Equitable US Cancer Clinical Trial Center Access by Travel Time
2024-03-2125 min
Lung Cancer ConsideredIASLC Lung Cancer Considered Drug Development and Targeted TherapiesIn this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses targeted therapies, what they are, and how they have changed our approach to treating not just lung cancer, but cancers in general.
Guest: Dr. Vivek Subbiah
Dr. Subbiah is the Chief of Early Phase Drug Development for Sarah Cannon Research Institute. He was previously the Executive Director of Medical Oncology Research for the MD Anderson Cancer Network, where he played a pivotal role in the development and ultimate approval for several agents that we consider essential in the lung cancer world.
2023-09-0550 min
Conference CoverageStudy Shows Importance of Comprehensive Genomic Profiling for NSCLC
Guest: Vivek Subbiah, MD
This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.
2023-06-1305 min
Project Oncology®Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
Guest: Vivek Subbiah, MD
This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.
2023-06-1305 minConference CoverageStudy Shows Importance of Comprehensive Genomic Profiling for NSCLC
Guest: Vivek Subbiah, MD
This episode will recap updates from the 2023 ASCO Annual Meeting regarding the abstract on comprehensive genomic profiling for non-small cell lung cancer (NSCLC). Join Dr. Vivek Subbiah, Chief of Early Drug Development at the Sarah Cannon Research Institute in Nashville, Tennessee, to learn more.
2023-06-1305 min
Healthcare UnfilteredEpisode 128: Debate of the Decade: RCTs in the Era of Precision OncologyHow do you design clinical trials in the era of precision oncology? Are prospective randomized controlled trials necessary anymore? Drs. Ray Kurzrock, Vivek Subbiah, and Christopher Booth drop the gloves and debate these questions - beginning with the definition of “precision oncology,” what phase the trials should be when initially designing, and whether accelerated approval and surrogate endpoints are truly helping patients in the precision oncology era. The group also analyzes specific examples of approved drugs and whether randomized controlled trials were and would have been good ideas prior to approval.Check out Chadi’s website for all Healthcare Unfilt...
2023-04-111h 20
PeerView Clinical Pharmacology CME/CNE/CPE VideoVivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other CancersGo online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel...
2023-03-021h 18
PeerView Oncology & Hematology CME/CNE/CPE Audio PodcastVivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other CancersGo online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel...
2023-03-021h 18
PeerView Oncology & Hematology CME/CNE/CPE Video PodcastVivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other CancersGo online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel...
2023-03-021h 18
PeerView Clinical Pharmacology CME/CNE/CPE Audio PodcastVivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other CancersGo online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel...
2023-03-021h 18
PeerView Gastroenterology CME/CNE/CPE Video PodcastVivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other CancersGo online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel...
2023-03-021h 18
PeerView Gastroenterology CME/CNE/CPE Audio PodcastVivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other CancersGo online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel...
2023-03-021h 18
PeerView Internal Medicine CME/CNE/CPE Audio PodcastVivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other CancersGo online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel...
2023-03-021h 18
PeerView Internal Medicine CME/CNE/CPE Video PodcastVivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other CancersGo online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel...
2023-03-021h 18
Illumina Genomics PodcastTesting for NTRK FusionsVivek Subbiah, MD, explains how patients with rare and common tumors can benefit from next generation sequencing (NGS)-based testing for NTRK gene fusions. He presents the case of a patient who benefited from precision medicine based on the detection of a NTRK1 fusion by comprehensive genomic profiling.
2022-11-1106 min
Healthcare UnfilteredEpisode 100: Synthetic Control Arms and the Regulatory MazeVivek Subbiah, MD, executive director of medical oncology research, MD Anderson Cancer Network, makes his triumphant return to the show to break down designing clinical trials for investigative therapies and the regulatory maze that follows before these therapies can find their way to the market. Dr. Subbiah begins by using precision medicine advances in lung cancer as a backdrop for the discussion on histology agnostic drug approvals. Then, he moves into the full regulatory flow map of how drugs make their way from phase I trials through FDA approval. The accelerated approval pathway, post-approval trials, synthetic control arms, off-label...
2022-09-201h 03
touchPODCASTPersonalized treatment of RET-altered thyroid cancerstouchEXPERT OPINIONS for touchENDOCRINOLOGY
Listen to leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers
The experts
Prof. Maria Cabanillas - University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Vivek Subbiah - University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Lori Wirth - Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical educational grant from Blueprint Medicines...
2022-03-1642 mintouchPODCASTPersonalized treatment of RET-altered thyroid cancerstouchEXPERT OPINIONS for touchONCOLOGY
Listen to leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers
The experts
Prof. Maria Cabanillas - University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Vivek Subbiah - University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Lori Wirth - Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant...
2022-03-1642 mintouchPODCASTPersonalized treatment of RET-altered thyroid cancerstouchEXPERT OPINIONS for touchONCOLOGY
Listen to leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers
The experts
Prof. Maria Cabanillas - University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Vivek Subbiah - University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Lori Wirth - Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant...
2022-03-1642 mintouchPODCASTPersonalized treatment of RET-altered thyroid cancerstouchEXPERT OPINIONS for touchENDOCRINOLOGY
Listen to leading experts explain the value of biomarker testing and targeted therapies for the personalized treatment of RET-altered thyroid cancers
The experts
Prof. Maria Cabanillas - University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Vivek Subbiah - University of Texas MD Anderson Cancer Center, Houston, TX, USA
Dr Lori Wirth - Center for Head and Neck Cancers, Massachusetts General Hospital, Boston, MA, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical educational grant from Blueprint Medicines...
2022-03-1642 min
AAOC Onco ArgentinaCambios de paradigmas en Cáncer anaplásico de tiroidesEl Dr. Raúl Giglio, Jefe del Servicio de Cabeza y Cuello del Instituto de Oncología Ángel Roffo, nos habla sobre el cambio de paradigmas en el tratamiento del cáncer anaplásico de tiroides BRAF+, un tumor infrecuente, de evolución tórpida que requiere una rápida acción para una mejor evolución y sobrevida del paciente.Con el apoyo de Novartis.Referencias: Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer, Vivek Subbiah et al., Journal of Clinical Oncology 2018 36:1, 7-13AG210922444
2021-11-1915 min
Healthcare UnfilteredEpisode 44: A Precise Depiction of Precision MedicineVivek Subbiah, MD, associate professor in the department of investigational cancer therapeutics, MD Anderson, is the world-renowned guest on the show this week to tackle the world of precision medicine in cancer. He begins by explaining how precision medicine is more than simply a “fancier” mechanism of treatment than chemotherapy, why tumor sequencing is important even though there aren’t drugs available for every possible mutation, how much the field has advanced even in the past 10 years, the intricacies of designing clinical trials, and lots more.
2021-08-171h 02
West Wind (Audio)Ishwaria & Vivek Subbiah (Part 2): Integrating Novel Treatments and Supportive Care in a Tertiary Care Referral CenterDrs. Ishwaria & Vivek Subbiah of MD Anderson Cancer Center review the challenges of weaving supportive care & symptom management with emerging targeted therapies & other novel treatments to blend into optimal cancer care.
2019-08-1229 min
West Wind (Audio)Ishwaria & Vivek Subbiah (Part 1): Origin Story for a Great Oncology Power CoupleDr. West speaks with Drs. Ishwaria & Vivek Subbiah from MD Anderson about their development to focus on supportive care & investigational therapies in cancer, respectively, & how they came together as a married couple living & working together.
2019-08-0832 min